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Abstract
This study sought to test whether targeted overexpression of osteoactivin (OA) in cells of osteoclastic lineage, using the
tartrate-resistant acid phosphase (TRAP) exon 1B/C promoter to drive OA expression, would increase bone resorption and
bone loss in vivo. OA transgenic osteoclasts showed ,2-fold increases in OA mRNA and proteins compared wild-type (WT)
osteoclasts. However, the OA expression in transgenic osteoblasts was not different. At 4, 8, and 15.3 week-old, transgenic
mice showed significant bone loss determined by pQCT and confirmed by m-CT. In vitro, transgenic osteoclasts were twice
as large, had twice as much TRAP activity, resorbed twice as much bone matrix, and expressed twice as much osteoclastic
genes (MMP9, calciton receptor, and ADAM12), as WT osteoclasts. The siRNA-mediated suppression of OA expression in
RAW264.7-derived osteoclasts reduced cell size and osteoclastic gene expression. Bone histomorphometry revealed that
transgenic mice had more osteoclasts and osteoclast surface. Plasma c-telopeptide (a resorption biomarker) measurements
confirmed an increase in bone resorption in transgenic mice in vivo. In contrast, histomorphometric bone formation
parameters and plasma levels of bone formation biomarkers (osteocalcin and pro-collagen type I N-terminal peptide) were
not different between transgenic mice and WT littermates, indicating the lack of bone formation effects. In conclusion, this
study provides compelling in vivo evidence that osteoclast-derived OA is a novel stimulator of osteoclast activity and bone
resorption.
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Introduction
Osteoactivin (OA), also known as Dchil (dendritic cell-associated,
heparin sulfate proteoglycan-dependent integrin ligand), Gpnmb
(glycoprotein non-metastatic melanomal protein B), or Hgfin
(hematopoietic growth factor-inducible neurokinin 1), is a type 1
transmembrane glycoprotein [1]. The OA gene, located on human
chromosome 7p15.1 or on mouse chromosome 6 [2], has 11 exons
with an open reading frame of 1,716 bp that encodes a protein of
572 amino acid residues. It has 13 N-linked glycosylation sites, a
heparin binding domain, an integrin-recognition RGD (Arg-Gly-
Asp) motif in both its extracellular and intracellular domains, and
a polycystic kidney disease (PKD) sequence [1,3]. OA may exist as
a 65-kD unglycosylated cellular protein or as multiple glycosylated
proteins with molecular size varying from 80-kD to 139-kD [4].
The transmembrane OAs can be proteolytically cleaved at their
juxtamembrane region by extracellular proteases, such as ADAMs
[5] and MMPs [6], in a process called ectodomain shedding,
which results in detachment and release of the extracellular
domain to act as cytokines or growth factors [7].
OA is expressed in a wide array of tissues and plays regulatory
roles in various cellular functions. Accordingly, OA plays a key
regulatory function in endothelial cell adhesion that involves
integrin binding [1]. High expression levels of OA protein can be
found in the nervous system, basal layer of the skin, germinal cells
of hair follicles, and the forming nephrons of the kidney of late
mouse embryos [2]. In immune cells, OA expression is associated
with cell differentiation, as its expression was detected in
differentiated macrophages, lymphocytes, and dendritic cells, but
undetectable in proliferating hematopoietic progenitors [8]. OA
plays a negative regulator role in activation of macrophages [9]
and T lymphocytes [10,11], and functions as an inhibitory
immune receptor [10]. In addition, OA is implicated in
development of retinal pigment epithelium and iris [12]. OA up-
regulates expression of matrix metalloproteinase (MMP)-3 and -9
in the infiltrating fibroblasts into denervated skeletal muscle [13].
Overexpression of OA in transgenic mice protects skeletal muscle
from severe degeneration and fibrosis caused by long-term
denervation [14] and reduces hepatic fibrosis in the injured or
diseased liver [15]. The ADAM10-released OA showed potent
angiogenic properties [5]. Because of its suggestive functions in cell
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tissues, OA has been implicated in physiological and pathophys-
iological cascades of tissue injury and repair [16]. In addition to its
diverse roles in normal cells and tissues, aberrant OA expression is
linked to various pathological disorders such as glaucoma [17],
kidney disease [18], osteoarthritis [19], and several types of cancer,
including: uveal melanoma [20], glioma [21], hepatocellular
carcinoma [22], and cutaneous melanoma [23].
In bone, OA was initially discovered by mRNA differential
display as a novel osteoblast-specific protein [3]. It was reported
that expression of OA is associated temporally with differentiation
and maturation of primary rat osteoblasts in vitro [2]. Suppressing
the OA functional activity with a blocking antibody reduced
differentiation and bone formation activity of rat osteoblasts
without affecting their proliferation and viability [24]. Bone
marrow mesenchymal cells derived from mutant mice expressing a
truncated OA lacking a large portion of the intracellular domain
were reported to be defective in their ability to differentiate into
osteoblasts in vitro [25]. These findings suggest that osteoblast-
derived OA has a regulatory role in osteoblast differentiation and
bone formation. OA expression in osteoblasts is up-regulated by
bone morphogenetic protein (BMP)-2 [26] through up-regulation
of binding of homeodomain transcription factors, Dlx3 and Dlx5
to the OA promoter [27]. OA appears to be a key mediator of the
BMP-2-induced osteoblast differentiation [26].
Studies from our group [4] and others [28] have demonstrated
that mature osteoclasts also express high levels of OA. In fact, the
expression level of OA in mature mouse osteoclasts was several-fold
in magnitude higher than that in mouse osteoblasts and stromal
cells [4,28], indicating that expression of OA in bone is not
restricted to osteoblasts. There is in vitro evidence that osteoclast-
derived OA has a stimulatory role in osteoclast maturation and
bone resorption [4]. However, the in vivo function of osteoclast-
derived OA in bone has not been investigated. The objective of
this study was to determine whether osteoclast-derived OA has a
regulatory role in bone resorption in vivo by determining the effects
of targeted overexpression of OA in cells of osteoclastic lineage with
the tartrate-resistant acid phosphatase (TRAP) exon 1B/C
promoter to drive transgenic OA expression in bone in vivo.W e
chose the TRAP-1B/C promoter over the TRAP-1C promoter,
which we used previously to generate transgenic mice with
targeted overexpression of an osteoclast-specific protein-tyrosine
phosphatase in osteoclasts [29], because the TRAP-1B/C
promoter is a stronger promoter than the TRAP-1C promoter in
vivo [30], although the TRAP-1B/C promoter is less specific for
osteoclasts than the TRAP-1C promoter [31].
Results
Generation of transgenic (Tg) mice with OA
overexpression in osteoclastic cells
OA-Tg founder mice were created by injecting the linearized
OA-Tg targeting expression plasmid (Fig. 1) into C57BL/6 (B6)
ova. The efficiency of generating Tg mice with B6 ova was low,
and only a total of 12 transgenic pups were obtained from two
separate injection procedures. Of these pups, three were shown to
be OA transgenic by a PCR-based genotyping assay. Additional
genotyping assays revealed that one of these transgenic pups
expressed a truncated form of OA lacking most of the intracellular
domain and was euthanized. The other two pups were confirmed
to be transgenic mice overexpressing the full-length OA in bone.
However, one of the OA-Tg lines was lost during breeding. Thus,
all subsequent studies were performed in the remaining OA-Tg
line. The transgenic founder was crossed with B6 mice to yield an
OA-Tg mouse colony of pure B6 genetic background.
Transgenic mice with overexpression of OA in cells of
osteoclast lineage (OA-Tg mice)
To confirm that osteoclasts of OA-Tg mice indeed overexpressed
OA, the relative levels of OA mRNA (by real-time RT-PCR) and
cellular OA protein (by Western immunoblots) were measured in
marrow-derived osteoclasts of 4-week-old female OA-Tg mice and
WT littermates. Fig. 2A shows that the two predominant
glycosylated OA protein species (i.e., ,130 kD and ,80 kD),
which are the functionally active species [2,4,6], in the OA-Tg
osteoclasts were each 2-fold of those in WT osteoclasts. We did not
determine cellular levels of the unglycosylated ,50–60 kD OA
protein species, because the polyclonal anti-OA antibody recog-
nizes primarily glycosylated species and does not detect unglyco-
sylated OA. Similarly, real-time RT-PCR analysis reveals that the
OA mRNA level in OA-Tg osteoclasts was significantly higher
(2.4060.51-fold, P=0.05) than that in WT osteoclasts (Fig. 2C).
Osteoblasts and marrow stromal cells also expressed TRAP [4].
To ensure that the use of TRAP-1B/C promoter to drive OA
expression would not also result in OA overexpression in
osteoblasts, we measured the OA mRNA and protein levels in
OA-Tg osteoblasts derived from OA-Tg mice. The level of the
predominant glycosylated OA protein, ,80 kD, in OA-Tg
osteoblasts was not significantly different from that in WT
osteoblasts (Fig. 2B), and the OA mRNA level in OA-Tg osteoblasts
was also not significantly different (0.6860.15-fold, p=N.S.) from
those in WT osteoblasts (Fig. 2C). Thus, the Tg mice generated
with the OA expression construct driven by the TRAP-1B/C
promoter did not result in significant OA overexpression in
osteoblasts. Fig. 2 also confirms our previous findings that the OA
protein level in osteoclasts was at least 2-fold higher than that in
osteoblasts [4], as the OA/actin ratio in WT osteoclasts was ,2-
fold of that in WT osteoblasts.
pQCT analyses of bone phenotype of OA-Tg mice
The body weight of OA-Tg mice of either sex at 8 weeks of age
was not different significantly from corresponding WT littermates
(Table 1). To evaluate the consequence of OA overexpression in
cells of osteoclastic lineage in the bone in vivo, we measured (with
Figure 1. Schematic representation of the pGL3-TRAP-1B/C-OA
expression plasmid. The pGL3-TRAP-1B/C-OA expression plasmid
was generated by cloning the full-length mouse OA cDNA into the
Hind3/XbaI restriction site of the pGL3-basic vector. The TRAP-1B/C
promoter was then cloned into the Kpn1/Hind3 restriction sites.
doi:10.1371/journal.pone.0035280.g001
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sites that are rich in trabecular bone (metaphyses) and cortical
bone (mid-diaphysis), respectively, in femurs of 8-week-old young
adult OA-Tg mice of both sexes (Table 1). The femur length of
female OA-Tg mice was 2.6% shorter (p,0.01) than female WT
littermates. In metaphysis at the secondary spongiosia, the Tg
mice had significantly 3–6% lower total, sub-cortical and cortical
BMD and area (but not trabecular BMD and area) than WT
littermates in either sex. The cortical thickness at this bone site of
OA-Tg mice of both sexes was also significantly smaller by 8%
than WT littermates. At mid-diaphysis, the total, subcortical, and
cortical BMD, and total bone area of OA-Tg mice were similarly
3–6% less compared to those of WT mice. The cortical thickness
at the mid-shaft of the femur of OA-Tg mice was smaller by 5–6%
than those of WT littermates. Accordingly, targeted overexpres-
sion of OA in cells of osteoclast lineage led to significantly lower
bone mass and BMD at the cortical bone site. There were no
apparent sex-related differences in the low bone mass phenotype
in these OA-Tg mice.
It has previously been reported that there were more abundant
TRAP-positive osteoclasts on bone surface of young growing mice
(e.g., 4 and 7 weeks of age) than fully grown adult mice (e.g., 14
weeks of age) [32]. Thus, it is possible that the basal TRAP-1B/C
promoter activity in mice may vary with age, which may in turn
lead to an age-dependent variation in OA overexpression levels in
OA-Tg mice. In this regard, Fig. 3 confirms that there was an age-
dependent variation in the relative OA overexpression level in OA-
Tg mice. The OA expression in the bone of 4 weeks old female OA-
Tg mice was 2- to 3-fold of that of age-matched female WT
littermates. The overexpression level was increased to 6-fold of
WT controls in 8 weeks old female OA-Tg mice. However, the OA
overexpression level in the bone of female OA-Tg mice at 15.3
weeks (107 days) of age was reduced to ,3-fold of WT controls.
To test whether this age-related difference in relative OA
overexpression levels in bone of OA-Tg mice would result in age-
dependent differences in the low bone mass phenotype, we also
determined the pQCT bone parameters of female OA-Tg mice of
4 weeks of age and of 15.3 weeks of age with respective age-
matched WT littermates. Table 2 shows that the 4-week-old
adolescent OA-Tg mice as well as the 15.3-week-old mature OA-Tg
mice each also exhibited similar low bone mass phenotype as those
seen in 8-week-old young adult mice (Table 1), although the
differences in bone parameters at metaphysis of the younger 4-
week-old OA-Tg compared to corresponding WT controls did not
reach statistically significant levels, presumably due to the
relatively large variations. Accordingly, the low bone mass
phenotype could also be seen at an age as early as after weanling
at 4-week-old and was maintained after they reached adulthood.
Two-factor ANOVA analysis confirms that both the age (i.e.,
growth) and the genotype (i.e., OA overexpression) had significant
effects on the various pQCT bone parameters (Fig. 4). However,
there was no significant interaction between the genotype and the
age of the animals, indicating that the age-related variations in OA
overexpression did not have synergistic effects on the low bone
mass phenotype.
m-CT analyses of the bone phenotype of OA-Tg mice
To further characterize the low bone mass phenotype, we
compared the m-CT bone mineral parameters in femurs of 4-
week-old female OA-Tg mice with those in femurs of 4-week-old
female WT littermates. Measurements at the midshaft, which
consists primarily cortical bone, show that the OA-Tg mice had
23.3% lower BV (0.32660.019 mm
3 for Tg mice vs.
0.42560.007 mm
3 for WT mice, p,0.005) and 10.8% lower
BV/TV (0.26460.010 mm
3/mm
3 for Tg mice vs.
0.29660.006 mm
3/mm
3 for WT mice, p,0.05) than WT
littermates. The tissue volume (TV) at this site was not significantly
different between the two groups (1.24860.122 mm
3 for Tg mice
vs. 1.43660.024 mm
3 for WT mice, p.0.05). These findings
confirm the pQCT findings that targeted overexpression of OA in
cells of osteoclast lineage caused a significant loss of cortical bone
mass. On the other hand, contrary to the pQCT results that
showed no significant decreases in trabecular BMD and BMC
(Table 1), the m-CT analysis clearly showed that these OA Tg mice
Figure 2. Expression levels of glycosylated OA protein species (A &B) and relative OA mRNA levels (C) in primary marrow-derived
osteoclasts and calvaria-derived osteoblasts derived from 4-week-old female OA-Tg mice or WT littermates. A: Top panel shows a
representative Western blot of the OA proteins level in osteoclasts from two OA transgenic (OA-Tg) mice or from two age- and sex-matched WT
littermates. Bottom panel summarizes the quantitative analysis of the relative density of the two predominant glycosylated OA protein species,
normalized against the density of the corresponding actin protein band (shown as mean 6 SEM). B: Top panel shows the Western blot of the OA
proteins level in primary osteoblasts of two OA-Tg mice and two WT littermates. Bottom panel summarizes the quantitative analysis of the relative
density of the ,80 kD glycosylated OA protein species (normalized against the density of the corresponding actin band). Results are shown as mean
6 SEM. C: Relative OA mRNA levels in cultured osteoclasts (left bar) and osteoblasts (right bar) of 4 weeks old female OA-Tg mice compared to age-
matched female WT mice. Results are shown as mean 6 SEM (n=4 for each).
doi:10.1371/journal.pone.0035280.g002
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(231.8%), connectivity density (228.6%), and Tb.Th (214.3%),
along with significant (p,0.05 for each) increases in Tb.Sp
(+16.8%) and structure model index (SMI, +35.5%) at the
trabecular bone-enriched secondary spongiosia site (Fig. 5).
Consequently, it appears that OA overexpression can cause
significant bone loss at both cortical and trabecular bone sites.
In addition, the significant decreases in connectivity density and
Tb.Th, along with an increase in SMI, are also consistent with an
increase in bone resorption in these OA-Tg mice.
Effects of targeted OA overexpression in osteoclastic cells
on bone resorption and osteoclast activity in vivo and in
vitro
To confirm that the low bone mass phenotype in OA-Tg mice
was indeed due to an increase in bone resorption, we first
determined static histomorphometric bone resorption parameters
at the secondary spongiosia of femurs of 4-week-old female OA-Tg
mice and WT littermates. Table 3 confirms that OA-Tg mice
indeed had significantly lower relative bone volume (%BV/TV,
215%). It also reveals that OA-Tg mice had significant increases in
osteoclast number (NOC, +26%), osteoclasts per total bone surface
(NOC/BS, +28%), and %TRAP-stained bone surface (TRAP.Pm,
+22%). The trabecular thickness (Tb.Th) was significantly reduced
by 15%. Although the OA-Tg mice also had lower trabecular
number (Tb.N) and larger trabecular spacing (Tb.Sp) than WT
littermates, the differences did not reach statistically significant
levels, perhaps due in part to the relatively small sample size
(n=5–6 per group). Thus, these findings not only demonstrate
that overexpression of OA in cells of osteoclast lineage increased
Table 1. Comparison of bone and pQCT parameters of 8 weeks old OA transgenic (Tg) mice with targeted OA overexpression in
osteoclastic cells to those of 8 weeks old sex-matched WT littermates (mean6SEM).
Males Females
Parameters WT (n=13) OA Tg (n=28) P WT (n=10) OA Tg (n=25) P
Body weight (g) 22.060.4 21.160.2 N.S. 17.660.3 17.360.16 N.S.
Femur length (mm) 14.136.11 14.096.08 N.S. 14.066.10 13.706.06 ,0.01
Metaphysis*
Total BMD (mg/cm
3) 444694 1 6 64 ,0.05 43065 41265 ,0.05
Subcortical BMD (mg/cm
3) 711686 7 7 64 ,0.001 72164 69267 ,0.001
Cortical BMD (mg/cm
3) 859688 3 0 63 ,0.01 87765 84767 ,0.01
Trabecular BMD (mg/cm
3) 239662 3 7 63 N.S. 18965 20066 N.S.
Total bone area (mm
2) 3.0360.04 2.9560.02 N.S. 2.796.03 2.626.05 ,0.005
Trabecular area (mm
2) 1.7260.02 1.7560.02 N.S. 1.536.04 1.506.04 N.S.
Subcortical bone area (mm
2) 1.3160.04 1.2060.02 ,0.05 1.266.02 1.116.02 ,0.001
Cortical bone area (mm
2) 0.8460.04 0.7360.01 ,0.05 0.816.02 0.696.02 ,0.001
Cortical thickness (mm) 0.2560.01 0.2360.00 ,0.01 0.256.01 0.236.00 ,0.005
Mid-diaphysis
#
Total BMD (mg/cm
3) 572635 4 2 63 ,0.001 53564 50668 ,0.01
Sub-cortical BMD (mg/cm
3) 892678 6 6 63 ,0.001 85566 825611 ,0.05
Cortical BMD (mg/cm
3) 106066 103263 ,0.001 102765 991611 ,0.01
Total bone area (mm
2) 1.9460.03 1.8560.01 ,0.05 1.796.03 1.786.05 N.S.
Sub-cortical area (mm
2) 1.1360.02 1.0460.01 N.S. 1.006.02 0.956.01 N.S.
Cortical bone area (mm
2) 0.8360.02 0.7660.01 ,0.05 0.726.02 0.676.01 0.055
Marrow area (mm
2) 0.8160.01 0.8060.01 N.S. 0.796.01 0.836.04 N.S.
Cortical thickness (mm) 0.2960.01 0.2760.00 ,0.001 0.276.00 0.266.00 ,0.05
*Metaphysis parameters were measured at 22% in length down from the distal end of the femur;
#Mid-diaphysis parameters were measured at the mid-shaft of the femur.
doi:10.1371/journal.pone.0035280.t001
Figure 3. Age effect on the relative overexpression levels of OA
mRNA in femurs of female OA-Tg mice. Total RNA was isolated
from femurs of female OA-Tg mice of age of 4-, 8-, and 15.3-week-old
and corresponding WT littermates (3–5 mice per group) and cDNA was
prepared as described in Methods. The relative level of OA mRNA,
determined by real-time RT-PCR and normalized against respective b-
actin mRNA level), is reported as fold of that in corresponding age-
matched WT osteoclasts (indicated by the dashed line) and shown as
mean 6 SEM (n=3–5).
doi:10.1371/journal.pone.0035280.g003
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(Fig. 5) that significant bone loss was seen in trabecular bones.
We next measured the circulating level of c-telopeptide of type I
collagen (a biomarker of bone resorption) in 8-week-old male
young adult OA-Tg transgenic mice and WT littermates. The
plasma level of c-telopeptide in OA-Tg mice was significantly
(p,0.05) higher (by 19.4%) compared to the WT littermates
(Fig. 6). This result, along with the increases in NOC, NOC/BS,
and TRAP.Pm, indicates that the low bone mass phenotype seen
in young adult OA-Tg mice is in a large part due to an increase in
bone resorption in vivo.
Because an increase in the size and/or nucleation of osteoclasts
is associated with an increase in functional activity, we also
determined whether targeted overexpression of OA in cells of
osteoclastic lineage would increase the size or nucleation of
osteoclasts on the bone surface in vivo. Fig. 7 shows that the average
size of osteoclasts (osteoclast size/osteoclast) on bone surfaces at
secondary spongiosia of 4-week-old female OA-Tg mice was
,70% (P=0.029) larger than those of WT littermates. The
average osteoclast surface per osteoclast (OC.PM/OC#) was also
,40% (P=0.046) greater in OA-Tg mice than in WT littermates.
Similarly, the number of nuclei per osteoclast was 2-fold
(P=0.012) greater in OA-Tg mice than in WT littermates.
We previously provided in vitro evidence that osteoclast-derived
OA plays an important functional role in osteoclast formation and
activity in part through promoting the RANKL-dependent fusion
and spreading of osteoclasts to form larger and functionally more
active osteoclasts [4]. To assess whether overexpression of OA in
osteoclastic cells has direct effects on osteoclasts, we compared the
relative cell size, TRAP expression level, and the in vitro bone
resorption activity of osteoclasts derived from marrow precursors
of adult OA-Tg mice with those of corresponding WT osteoclasts.
Fig. 8 shows that the marrow-derived TRAP
+, multinucleated,
osteoclasts of 12-week-old OA-Tg mice were twice as large (Figs. 8A
and B), contained more nuclei (Fig. 8A), expressed twice as much
TRAP activity (Fig. 8C), and produced twice as large resorption
pits (Fig. 8D), as control WT marrow-derived osteoclasts in vitro.I n
addition, marrow-derived osteoclasts of OA-Tg mice also expressed
significantly higher levels of metalloprotease-9 (MMP9) mRNA [a
critical degradative enzyme for osteoclastic resorption], calcitonin
receptor (CALCR) mRNA [a marker gene for mature osteoclasts],
and ADAM12, but not MMP3 mRNA, than WT osteoclasts
(Fig. 8E). The phosphotyrosine-527 (PY-527) level of Src in OA-Tg
osteoclasts was approximately one-half as that in WT osteoclasts
(Fig. 8F). Because the protein-tyrosine kinase (PTK) activity of Src
is negatively regulated by its PY-527 level, the PTK activity of Src
or its signaling pathway could be twice as active in Tg osteoclasts
as in WT osteoclasts. To evaluate whether overexpression of OA in
osteoclastic cells might also affect the differentiation and formation
of osteoclasts in vitro, we counted the total number of TRAP-
expressing, multinucleated (two or more nuclei) osteoclasts formed
from treating marrow-derived osteoclast precursors of five 4-week-
old female OA-Tg mice and four 4-week-old female WT
littermates after 4 days of the RANKL and m-CSF treatment in
vitro. While precursors of OA-Tg mice yielded bigger TRAP
positive osteoclast-like cells, there was no significant difference in
the total number of osteoclasts derived from marrow-derived
precursors of OA-Tg mice and from those of WT littermates
(Fig. 8G), suggesting that OA in osteoclasts is a potent enhancer of
osteoclast fusion and activation but not a major regulator of
osteoclast formation.
To determine if siRNA-mediated suppression of OA expression
in RAW264.7 cell-derived osteoclast-like cells would yield opposite
effects on the cell size (Fig. 9A) and expression of key osteoclastic
Figure 4. Age effects on relative differences in pQCT bone parameters between OA-Tg mice and corresponding WT littermates. The
femur length (A), total BMD (B), cortical bone area (C), cortical thickness (D), cortical BMD (E), and subcortical BMD (F) at midshaft of femur of female
OA-Tg mice and corresponding WT littermates of 4, 8, and 15.3 weeks of age were each plotted against corresponding age of the animals. Statistical
significance of age, genotype, and age6genotype interaction was determined by two-factor ANOVA.
doi:10.1371/journal.pone.0035280.g004
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siRNAs (denoted as OA siRNA #1 and OA siRNA #2,
respectively) for 6 hrs prior to RANKL treatment to form
osteoclast-like cells. Both siRNAs suppressed OA mRNA and OA
protein expression by .70% and .80%, respectively (data not
shown), and each significantly reduced the average cell size of the
derived osteoclast-like cells as well as decreased in vitro bone
resorption activity (Fig. 9B). Thus, subsequent siRNA studies used
only OA siRNA#1. The OA siRNA-treated osteoclast-like cells
expressed significantly less MMP9 mRNA and CALCR mRNA
(Fig. 9C). The siRNA treatment did not have a significant effect on
the NFAT-c1 mRNA [an essential transcription factor for
osteoclast differentiation and formation] level, supporting our
contention that OA is not an essential regulator of osteoclast
differentiation and formation.
Effects of targeted OA overexpression in osteoclastic cells
on bone formation in vivo and osteoblast activity in vitro
The shedded OA has been shown to be a potent stimulator of
osteoblast differentiation [24–26]. To evaluate whether overex-
pression of OA in TRAP exon 1B/C-expressing cells would release
shedded OA protein to act on nearby osteoblasts to stimulate
osteoblast differentiation and bone formation, we measured
dynamic histomorphometric bone formation parameters at the
midshaft of longitudinal sections of femurs of 8-week-old male OA-
Tg mice with that of male WT littermates (Table 4). Overexpres-
sion of OA in TRAP-expressing cells not only did not increase any
of the test histomorphometric bone formation parameters but
instead significantly reduced the bone surface and total tetracy-
cline-labeling surfaces. Measurements at the endosteal bone
surface of cross-sections of femur at the midshaft of 15.3-week-
old female OA-Tg mice also showed significant reduction in
endosteal mineralization apposition rate and endosteal bone
formation rate when compared to age-matched female WT
littermates. To determine whether overexpression of OA in
osteoclasts would affect the number of ALP-expressing osteoblasts
along the bone surface in vivo, we counted the ALP-expressing
osteoblasts on the trabecular bone surface of 4 weeks-old female
OA-Tg mice and WT littermates and normalized them against
total bone surface or tissue area (Table 5). There were no
significant differences in the number of osteoblasts per bone
surface (NOB/BS) or the number of osteoblasts per tissue area
(NOB/TA). There was also no significant difference in the
osteoblast surface per bone surface (OB.PM/BS), indicating that
targeted overexpression of OA in cells of osteoclastic lineage did
not alter osteoblast activation or increase osteoblastic surface on
trabecular bone.
To confirm the lack of bone formation effects, we measured
plasma levels of biomarkers of bone formation in the OA-Tg mice.
Plasma osteocalcin level of 8-week-old female OA-Tg mice was not
different from that of age-matched WT littermates, while the
plasma osteocalcin level of 15.3-week-old OA-Tg mice was even
slightly (close to, but not statistically significant, P=0.09) lower
than that of age-matched WT mice (Fig. 10A). Similarly, plasma
level of another bone formation biomarker, pro-collagen type I N-
terminal peptide (PINP), of 15.3-week-old female OA-Tg mice of
both sexes was also slightly, but not significantly, reduced when
Table 2. Comparison of bone pQCT parameters of weanling young (4-week-old) female OA-Tg mice and mature adult (15.3-week-
old) female OA-Tg mice with those of corresponding age-matched female WT littermates (mean 6 SEM).
4-week-old 15.3-week-old
Parameters WT (n=10) OA Tg (n=20) P WT (n=14) OA Tg (n=19) P
Femur length (mm) 11.8360.11 11.2160.19 ,0.05 15.3460.07 15.2260.05 N.S.
Metaphysis*
Total BMD (mg/cm
3) 326.266.3 313.869.9 N.S. 508.266.2 520.865.7 N.S.
Subcortical BMD (mg/cm
3) 551.3613.8 523.4612.5 N.S. 809.166.4 802.264.3 N.S.
Cortical BMD (mg/cm
3) 737.865.7 728.065.8 N.S. 961.366.8 949.265.0 N.S.
Trabecular BMD (mg/cm
3) 220.165.8 220.069.6 N.S. 221.763.8 236.365.0 ,0.05
Total bone area (mm
2) 2.9560.09 2.9460.07 N.S. 2.8560.07 2.6660.03 ,0.05
Trabecular area (mm
2) 2.0160.07 2.0460.04 N.S. 1.4660.05 1.3260.02 ,0.05
Subcortical bone area (mm
2) 0.9360.03 0.9060.04 N.S. 1.3960.03 1.3460.02 N.S.
Cortical bone area (mm
2) 0.3860.03 0.3760.02 N.S. 0.9860.03 0.9560.01 N.S.
Cortical thickness (mm) 0.1760.00 0.1660.01 N.S. 0.2760.00 0.2760.00 N.S.
Mid-diaphysis
#
Total BMD (mg/cm
3) 410.265.7 381.7611.6 ,0.05 634.466.5 627.565.0 N.S.
Sub-cortical BMD (mg/cm
3) 686.868.3 649.2616.4 ,0.05 968.068.1 949.563.7 ,0.05
Cortical BMD (mg/cm
3) 840.968.2 806.6613.3 ,0.05 1138.668.0 1117.364.0 ,0.05
Total bone area (mm
2) 1.4560.04 1.4160.03 N.S. 2.0460.06 1.8260.02 ,0.05
Sub-cortical area (mm
2) 0.7260.02 0.6660.02 ,0.05 1.2360.04 1.1560.01 ,0.05
Cortical bone area (mm
2) 0.4660.02 0.3960.02 ,0.05 0.9460.03 0.8760.01 ,0.05
Marrow area (mm
2) 0.7360.02 0.7560.01 N.S. 0.8160.02 0.7360.01 ,0.05
Cortical thickness (mm) 0.2160.01 0.1960.01 ,0.05 0.3160.01 0.3060.01 ,0.05
*Metaphysis parameters were measured at 22% in length down from the distal end of the femur;
#Mid-diaphysis parameters were measured at the mid-shaft of the femur.
doi:10.1371/journal.pone.0035280.t002
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(Fig. 10B).
Discussion
In this study, we have obtained compelling in vivo evidence that
osteoclast-derived OA has essential functions in regulating
osteoclast activity and in bone resorption. Accordingly, this study
shows that targeted overexpression of OA to cells of osteoclastic
lineage led to substantial loss of bone mass and density in OA-Tg
mice. Although pQCT measurements failed to detect significant
loss of bone mass at trabecular bone sites of OA-Tg mice, bone
histomorphometry and m-CT analyses each indicate substantial
loss of bone mass in trabecular bone. The reason for the failure in
detecting bone loss at trabecular bone sites by pQCT is unclear.
Nevertheless, based on the m-CT and histomorphometry findings,
we conclude that targeted overexpression of OA in cells of
osteoclast lineage would lead to loss of bone mass at both cortical
Figure 5. Comparison of m-CT bone parameters at the
secondary spongiosa of 4-week-old female OA-Tg mice with
those of 4-week-old female WT littermates. Top panels show the
three-dimensional reconstruction of bone structure by m-CT at the
secondary spongiosa of two representative OA-Tg mice (right) and two
WT littermates (panel). Bottom summarizes and compares the various
m-CT bone parameters of a group of four OA-Tg mice with a group of
four WT littermates.
doi:10.1371/journal.pone.0035280.g005
Table 3. Comparison of static histomorphometric trabecular bone parameters at the secondary spongiosa of 4-week-old female
OA-Tg mice with age- and sex-matched WT littermates (mean 6 SEM).*
Parameters WT Littermates (n=6) OA Tg Mice (n=5) vs. WT controls P
Tissue area (mm
2) 0.84260.031 0.86860.024 +3.1% N.S.**
Bone area (mm
2) 0.15860.009 0.13960.006 212.0% N.S.
Bone surface (mm) 10.2860.51 10.1460.66 21.4% N.S.
%BV/TV*** (%) 18.8260.87 16.0660.66 214.7% ,0.05
Total NOC (#) 155.764.9 195.6624.9 +25.6% N.S.
NOC.PM (mm
21) 8.0160.42 10.2560.49 +28.0% ,0.01
TRAP.PM (%) 40.7761.70 49.7662.09 +22.1% ,0.05
Tb.N (#) 7.2060.31 6.6160.23 28.2% N.S.
Tb.Th (mm) 0.02660.001 0.02260.000 215.4% ,0.05
Tb.Sp (mm) 0.11460.007 0.12960.005 +13.1% N.S.
*Measurments were performed at a site that was 300 mm away from the growth plate.
**N.S.=Not significant.
***% (BV/TV), trabecular area per total tissue area in percentage; Total OC#, total number of TRAP positive multinucleated osteoclasts; OC#.PM, number of TRAP
positive osteoclasts per bone surface length; TRAP.PM, TRAP-stained bone surface per total tissue area; Tb.N, trabecular number; Tb.Th, trabecular thickness; and Tb.Sp,
trabecular spacing.
doi:10.1371/journal.pone.0035280.t003
Figure 6. Targeted overexpression of OA in cells of osteoclastic
lineage increased circulating levels of c-telopeptide of type I
collagen. Plasma c-telopeptide levels of 8-week-old male young adult
OA-Tg mice (n=17) and WT littermates (n=12) were measured with a
commercial ELISA assay, and results are shown as mean 6 SEM.
doi:10.1371/journal.pone.0035280.g006
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in NOC.PM, TRAP.PM, and Tb.Sp, along with a decrease in
Tb.Th, as well as an elevated plasma level of c-telopeptide in OA-
Tg mice compared to age- and sex-matched WT littermates
strongly indicate that osteoclast-derived OA has essential regula-
tory roles in bone resorption in vivo. In contrast, histomorphomet-
ric bone formation parameters, number of osteoblasts per bone
surface length, and plasma levels of osteocalcin and PINP in OA-
Tg mice were not different from those in WT littermates. These
findings led to our conclusion that the bone loss in OA-Tg mice is
due to an increase in bone resorption and not to reduction in bone
formation.
Two observations in this study are noteworthy. First, in vitro
characterization of marrow-derived osteoclasts from OA-Tg mice
indicates that marrow-derived osteoclasts of OA-Tg mice were
significantly larger, contained more nuclei, and produced larger
resorption pits in the in vitro resorption pit formation assay than
osteoclasts derived from WT mice. These observations confirm
our previous in vitro findings [4] that OA has enhancing effects on
osteoclast maturation, fusion, and spreading, and also in their in
vitro bone resorption activity. Interestingly, overexpression of OA in
osteoclasts upregulated expression of genes associated with
osteoclastic activity (e.g., Mmp9 and Calcr), but not those associated
with osteoclast formation (e.g., Nfatc1), suggesting that osteoclast-
derived OA promotes bone resorption primarily through activation
of osteoclasts rather than osteoclast formation. This tentative
conclusion is supported by both in vivo and in vitro evidence: first,
overexpression of OA in cells of osteoclastic lineage did not alter
significantly the total number of osteoclasts but increased markedly
the percentage of osteoclastic surface (TRAP.PM) on bone surfaces
in vivo. Second, while treatment of marrow-derived precursors of
OA-Tg mice with RANKL yielded significantly larger TRAP-
expressing osteoclasts than those of WT littermates in vitro, the total
number of osteoclasts derived from precursors of both OA-Tg and
WT mice was not significantly different.
With respect to the potential molecular mechanism by which
OA stimulates osteoclast activity, our previous in vitro studies in
Figure 7. Effects of targeted overexpression of OA in osteo-
clastic cells on the size and number of nuclei of osteoclasts in
vivo. Top panel of Fig. 7 shows photomicrographs of the TRAP-
expressing osteoclasts (counter-stained with hematoxylin) on the
trabecular bone surface at secondary spongiosa of a WT mouse and
an OA-Tg mouse. Bottom panels show the quantitative differences in
osteoclast size per osteoclast (left), osteoclast surface per osteoclast
(OC.PM/OC, middle), and number of nuclei per osteoclast (right)
between six OA-Tg mice and four WT littermates. Results are shown as
mean 6 SEM.
doi:10.1371/journal.pone.0035280.g007
Figure 8. Effects of overexpression of OA on relative size of marrow-derived osteoclasts (A and B), and TRAP expression levels (C),
size of resorption pits formed in vitro (D), expression levels of bone resorption genes (E), cellular Src tyrosine-527 phosphorylation
level (F), and number of TRAP-expressing osteoclast-like cells formed in response to the RANKL and m-CSF treatment (G). In A–F,
marrow-derived osteoclasts were generated from treatment of unattached marrow cells of 12-weeks-old male adult OA-Tg mice and corresponding
WT littermates with RANKL and m-CSF for 7 days. In A, to identify the size of osteoclasts, actin rings were stained with FITC-Palloidin and visualized
under a fluorescent microscope. Results are shown in mean 6 SEM (n=3 each for each parameter). In G, marrow-derived osteoclasts were generated
by treating unattached marrow cells of five 4-weeks-old female OA-Tg mice or four 4-weeks-old female WT littermates. Results are shown as mean 6
SEM.
doi:10.1371/journal.pone.0035280.g008
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OA-induced activation of the integrin signaling (presumably
through the RGD-depending OA interaction with integrins) [4].
The integrin signaling in osteoclasts is a key mechanism mediating
cytoskeleton reorganization, which is required for all essential
processes associated with osteoclast activation, including cell
fusion, attachment, polarization, and construction of the sealing
zone and ruffled borders [33]. Activation of the Src PTK through
dephosphorylation of the inhibitory PY527 residue [34] is one of
the critical steps involved in the integrin signaling in osteoclasts
[35]. In this regard, the finding that OA-Tg osteoclasts showed
significant lower Src PY527 level than WT osteoclasts is consistent
with an activation of the Src signaling in OA-Tg osteoclasts. This
finding, along with the observations that OA-Tg osteoclasts are
larger and more spread out, is consistent with the hypothesis that
the OA-induced activation of osteoclast activity may involve Src
activation and integrin signaling in osteoclasts. This interesting
hypothesis will be evaluated in our future studies.
The second intriguing observation is related to the absence of an
increase in bone formation in the transgenic mice. OA belongs to a
unique family of transmembrane proteins, which can shed their
extracellular domain through proteolysis mediated by extracellular
proteases (sheddases) that include various members of the ADAM
[5] and MMP [6] families. In bone, the shedded ectodomain of
OA has been suggested to function as autocrine/paracrine factor
to promote osteoblast differentiation [2,3,24–27]. Activated
osteoclasts also shed the ectodomain of osteoclast-derived OA,
which also acts as autocrine/paracrine factor to stimulate
osteoclast activity [4]. We had hypothesized that overexpression
of OA in osteoclastic cells would result in increased shedding of
ectodomain of osteoclast-derived OA, which then acts as a
paracrine osteogenic factor on nearby osteoblast precursors to
promote bone formation in vivo. The findings that overexpression
of OA in osteoclasts led to upregulation of Mmp9 and Adam12
expression (two extracellular proteases that mediate the shedding
of ectodomain of membrane-bound OA) in osteoclasts of OA-Tg
Figure 9. Effects of siRNA-mediated OA suppression on average cell size (A), in vitro bone resorption activity (B), and expression of
osteoclastic genes (C) in RAW264.7 cell-derived osteoclast-like cells. The dosage of OA siRNAs (29 pM) used in this experiment suppressed
OA expression in RAW264.7 cells by greater than 70% (data not shown). RAW264.7 cells were treated with OA siRNAs or control siRNA in the presence
of RANKL for 5 days. A shows the relative size of the derived TRAP positive, multinucleated osteoclast-like cells. Top is a representative
photomicrograph of the derived osteoclast-like cells, and bottom summarizes the relative size (in relative percentage of the control siRNA-treated
cells). B shows the bone resorption activity of the derived osteoclast-like cells determined by an in vitro resorption pit formation assay; and C
summarizes the effects of OA siRNA on the relative expression levels of MMP9, CALCR, and NFATc1 mRNA (determined by real-time RT-PCR and
normalized by the respective expression level of b-actin). Results are shown as percentage of respective control siRNA-treated RAW264.7 cell-derived
osteoclast-like cells and in mean 6 SEM (n=3 or 4 for each parameter). The dashed line represents the 100% of the control siRNA-treated controls.
doi:10.1371/journal.pone.0035280.g009
Table 4. Effects of targeted overexpression of OA
overexpression in osteoclastic cells on histomorphometric
bone formation parameters in 8-week-old male OA-Tg and
also in 15.3-week-old female OA-Tg mice (mean6SEM).
Parameters WT OA-Tg P
8 weeks old male mice*
BS (mm) 2.6360.12 2.2560.05 ,0.05
TLS (mm) 2.6360.07 2.2860.06 ,0.05
MAR (mm/day) 3.3060.40 2.8460.30 N.S.
BFR (mm
2610
23/day) 8.8361.28 6.5160.72 N.S.
TLS/BS (mm/mm) 0.9960.03 1.0060.02 N.S.
BFR/BS (mm
2610
23/mm
2/day) 3.3560.46 2.9260.33 N.S.
15.3 weeks old female mice
#
E.BS (mm) 0.8460.02 0.8460.01 N.S.
E.TLS (mm) 2.3260.14 2.1460.12 N.S.
E.MAR (mm
2610
23/day) 1.1260.05 0.9460.04 ,0.05
E.BFR (mm
2610
23/day) 2.6160.20 2.0360.20 0.05
E.TLS/E.BS (mm/mm) 0.6560.04 0.5960.03 N.S.
E.BFR/E.BS (mm
2610
23/mm
2/day) 3.1260.27 2.3960.20 ,0.05
BS, bone surface; TLS, tetracycline labeling surface; MAR, mineralization
apposition rate; BFR, bone formation rate; E.BS, endosteal bone surface; E.TLS,
endosteal tetracycline labeling surface; E.MAR, endosteal mineralization
apposition rate; E.BFR, endosteal bone formation rate.
*Dynamic bone formation parameters were performed on longitudinal sections
of femurs of 7 WT littermates and 13 OA-Tg mice at the cortical bone site of the
mid-shaft, starting from 1.2 mm from the lowest point, 2 grids under a 106
microscope lens.
#Dynamic bone formation parameters were performed on the endosteal
surface of femurs of 8 WT littermates and 11 OA-Tg mice.
doi:10.1371/journal.pone.0035280.t004
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osteoclast-derived OA from Tg osteoclasts. Therefore, we were
surprised by the absence of corresponding increases in bone
formation in OA-Tg mice. One of the possibilities for the lack of an
increase in bone formation is that the amounts of the shedded
ectodomain of osteoclast-derived OA might not have been
sufficient to elicit an anabolic response on osteoblasts that would
yield an increase in bone formation. Bone marrow mesenchymal
cells derived from mutant mice expressing a truncated OA lacking
a large portion of the intracellular domain have been shown to be
unable to differentiate into osteoblasts in vitro [25]. Thus, an
alternative possibility is that the intracellular domain (rather than
the shedded ectodomain) of OA in osteoblasts is essential for the
osteogenic response. We also cannot dismiss the possibility that the
acidic and proteolytic environment of the resorption cavity might
have further degraded the shedded ectodomain, rendering it
nonfunctional in stimulating the differentiation and activity of
nearby osteoblast precursors.
Understanding of the regulation of OA gene expression in
osteoclasts could provide important insights into its functional role
in osteoclastic resorption. While very little is known about the
regulation of OA expression, this study and our previous studies [4]
have shown that OA in osteoclastic cells is up-regulated by
RANKL in time- and dose-dependent manner. Accordingly,
treatment of osteoclasts precursors with RANKL could result in
hundreds- or even thousands-fold increase in OA expression. In
light of the well established fact that RANKL is a potent stimulator
of osteoclast differentiation and activity and also the well known
complexity of the RANKL signaling networks in the stimulation of
osteoclast differentiation and activity [36], it is possible that OA
may yet be another novel mediator of the RANKL signaling
mechanism in osteoclasts. However, previous studies showed that
OA expression is strongly up-regulated by IFN-c and lipopolysac-
charide in macrophages [9], and that BMP-2 markedly stimulates
OA expression in rat osteoblasts [26]. Because IFN-c [37] and
BMP-2 [38] have each been shown to be capable of acting directly
on osteoclast precursors to promote their differentiation and
activity, we cannot rule out the possibility that the molecular
mechanism of these two effectors to stimulate osteoclast differen-
tiation and bone resorption may also involve in the up-regulation
of OA expression in osteoclastic cells. Our future work will evaluate
these interesting possibilities.
In summary, this study demonstrates for the first time that the
osteoclast-derived OA is a novel regulator of osteoclastic
resorption in vivo. This study also provided compelling evidence
that targeted overexpression of OA in cells of osteoclastic lineage
with TRAP-1B/C promoter, while markedly increased the bone
resorption activity of osteoclasts (and thereby bone resorption), but
without an appreciable effects on bone formation in vivo.
Understanding the mechanism by which OA regulate the
osteoclast activity would not only yield important information
about its functional role in the overall regulation of osteoclastic
resorption, but might also offer significant insights into the
pathophysiology of various bone-wasting disorders, including
osteoporosis. More importantly, it may also provide novel gene
or pathway targets for development of novel and effective therapy
for bone-wasting disorders (such as osteoporosis) or fracture repair,
as OA or its downstream effectors may be used as screening targets
for identifying novel, specific, and safer modulators of bone
resorption.
Table 5. Comparison of osteoblast parameters at secondary spongiosa* of 4-week-old female OA-Tg mice with 4-week-old female
WT littermates (mean 6 SEM).
Parameters WT Littermates (n=4) OA Tg Mice (n=7) vs. WT controls P
NOB/BS** (1/mm) 22.7661.67 22.9862.47 +0.9% N.S.***
NOB/TA (1/mm
2) 273.88629.04 253.73643.76 27.4% N.S.
OB.PM/BS (mm/mm) 28.9362.51 29.3662.77 +1.5% N.S.
*Measurements were performed at a site that was 300 mm away from the growth plate.
**NOB.BS, number of ALP positive osteoblasts per bone surface length; NOB/TA, number of osteoblasts per total tissue area; and OB.PM/BS, osteoblast surface length
per total bone surface length.
***N.S.=Not significant.
doi:10.1371/journal.pone.0035280.t005
Figure 10. Effects of targeted overexpression of OA in osteoclastic cells on plasma levels of biomarkers of bone formation in vivo. In
A, plasma levels of osteocalcin of female OA-Tg mice and WT littermates of 8 or 15.3 weeks of age were measured with a commercial ELISA kit. Results
are shown as mean 6 SEM with the indicated the number of mice per group. In B, plasma levels of pro-collagen type I N-terminal peptide (PINP) of
both male and female 15.3-week-old OA-Tg mice and corresponding age- and sex-matched WT littermates were measured with a commercial ELISA
kit. Results are shown as mean 6 SEM with the indicated number of mice per group.
doi:10.1371/journal.pone.0035280.g010
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Animals
Osteoclastic-specific OA transgenic (OA-Tg) founder mice were
generated in C57BL/6J (B6) genetic background by the
Transgenic Core Facility of the University of California at Irvine
using an established approach similar to that previously described
for PTP-oc transgenic mice [29]. The OA expression is driven by
TRAP-1B/C promoter. Very briefly, the pGL3-TRAP-1B/C-Luc
plasmid [30] was a generous gift from Dr. A. Ian Cassady of the
University of New England in Armidale, New South Wales,
Australia. The pGL3-TRAP-1B/C-OA expression plasmid (Fig. 1)
was generated by cloning into the pGL3-basic vector containing
the TRAP-1B/C promoter at the Kpn1/Hind3 restriction sites and
the long PCR-cloned full-length murine OA cDNA at the Hind3
and Xba1 sites. The linearized transgenic plasmid was then
injected into B6 ova to generate OA-Tg founder mice.
Identification of OA-Tg mice were accomplished with a PCR-
based genotyping assay. Briefly, a small piece of tail tissue was
taken from each pup at weaning and genomic DNA was isolated
with the Qiagen DNAeasy Blood & Tissue kit (Qiagen, San Diego,
CA) according to the supplier’s recommended procedure. The
quality and quantity of the genomic DNA were analyzed with the
nanodrop ND-1000 spectrophotometer (ThermoFisher Scientific,
Los Angeles, CA). The PCR-based genotyping reaction was
performed using the following set of primers: the forward primer,
which corresponds to a unique region of the 59-region of the
mouse TRAP-1B/C promoter (from 21,331 of promoter 1C), was
59-TCC TCG GAG AAA ATG CAT CA-39, and the reverse
primer, which corresponds to a unique region of the murine OA
sequence (from 565 of OA open reading frame), was 59-CTG
GCC AAG TGT GTG AAA GA-39. The PCR condition included
a 5-min hot start at 94uC and 35 cycles of amplification, each
consisting of 30 sec at 94uC, 30 sec at 55uC, and 1 min at 72uC.
This was then followed by a final 10 min at 72uC. The PCR
product was analyzed by agarose gel electrophoresis. Genomic
DNA of transgenic mice but not WT littermates yielded a single
PCR band of 875-bp. The animal use component was approved
by the Animal Care and Use Committees of both the Jerry L.
Pettis Memorial VA Medical Center and the Loma Linda
University. The entire study has also been reviewed and approved
by the Research and Development committee of the Jerry L. Pettis
Memorial VA Medical Center.
Bone parameter measurements
Bone parameters were determined by peripheral Quantitative
Computed Tomography (pQCT) as previously described [29]
using a Norland Stratec XCT 960 M pQCT. Trabecular bone
parameters were determined with threshold setting of 230–
630 mg/cm
2. A threshold setting of 630 mg/cm
2 was used to
determine cortical bone parameters.
The bone phenotype of the femur of groups of transgenic mice
or age- and sex-matched WT littermates was also assessed by m-
CT using a Scanco vivaCT40 m-CT scanner (Scanco Medical,
Bru ¨ttisellen, Switzerland) at the secondary spongiosa of the distal
femur as described previously [29]. Briefly, the femur was placed
in a 1.7-ml Eppendorf tube and was scanned using high resolution
(55,000 V with an intensity of 145 mA). Thirty-six slices (360 mm)
distal from the bottom of the growth plate were excluded to avoid
the entire primary spongiosa. The trabecular bone was scanned at
10-mm slices at 10-mm increments to cover a total distance of
1.8 mm. The scanned image was contoured to exclude cortical
bone and focused only on trabecular bone. The slices were
analyzed using the threshold setting of 230–1,000 mg/cm
3. Bone
parameters were calculated using the analytical tool software of
Scanco.
Bone histomorphometry
Bone mass and resorption histomorphometric parameters were
measured at the secondary spongiosia of the tibia as described
previously [39].
Cell cultures
Primary bone marrow cells, flushed out of long bones of adult
OA-Tg or WT mice, and marrow-derived osteoclasts were
generated from non-adherent marrow cells stimulated with
RANKL and m-CSF as previously described [12,14]. Osteoblasts
were isolated from calvaria of adult OA-Tg or WT by 90 min
crude collagenase digestion as previously described [12].
RAW264.7 cell-derived osteoclast-like cells were produced as
described previously [17].
Plasma biomarker assays
The plasma biomarker of bone resorption, c-telopeptide levels,
were measured with a commercial mouse CTX-I ELISA kit
according to introduction provided by the supplier (Immunodiag-
nosticsystem, Inc., Fountain Hills, AZ). Plasma levels of bone
formation biomarkers [osteocalcin levels and pro-collagen I N-
terminal peptide (PINP)] were determined with commercial mouse
serum osteocalcin ELISA kit (Biomedical Technologies, Inc.,
Stoughton, MA) and mouse PINP ELISA kit (Immunodiagnos-
ticsystem, Inc., Fountain Hills, AZ), respectively.
siRNA experiments
Two small interfering RNA duplexes (siRNAs) specific for
mouse OA and a non-silencing control siRNA without any
homology to known mouse genes, which have been described
previously [4], were synthesized by Qiagen. [Target sequence for
OA siRNA #1: ATG AGA GAG CAC AAC CAA TTA (Cat #
S100230937); target sequence for OA siRNA #2: TAC CTT GAT
GAA GGT AGA CAA (Cat # S102720235)]. For the siRNA
experiment, RAW264.7 cells were transfected with the test
siRNAs using the HiPerFect Transcription reagent (Qiagen).
The effectiveness of OA suppression after an additional 24–48 h of
incubation at 37uC was assessed by real-time RT-PCR and
Western immunoblot using an anti-OA antibody. After siRNA
transfection, RAW264.7 cells were treated with RANKL to
differentiate into osteoclast-like cells for evaluation.
Western immunoblot assays
Western analyses were performed as previously described [4],
and quantified with an LI-COR Odyssey Infrared Imaging System
(LI-COR Biosciences, Inc., Lincohn, NE).
Gene expression levels
mRNA levels of each gene-of-interest were measured by real-
time RT-PCR, using an ABI 7500 FAST real-time PCR system
(Applied Biosystems, Inc., Foster City, CA). The primer sets of
each gene-of-interest are shown in Table 6.
Statistical analyses
Statistical significance of differences between the transgenic and
the WT group is determined by two-tailed Student’s t-test. The
interaction between the age and genotype effect was assessed with
two-way ANOVA analyses. The difference is considered statisti-
cally significant, when p,0.05. Data are reported as the mean 6
standard error of the mean (SEM).
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